Residual Pulmonary Vascular Obstruction Index Computed with Ventilation/perfusion SPECT/CT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients with Pulmonary Embolism (PRONOSPECT) (PRONOSPECT)

Residual Pulmonary Vascular Obstruction (RPVO) Index Computed with Ventilation/perfusion SPECT/CT Imaging to Predict the Risk of Venous Thromboembolism (VTE) Recurrence in Patients with Pulmonary Embolism (PE)

Major risk after pulmonary embolism (PE) is recurrence, fatal in 10% of patients. Patients with PE can be stratified in 3 groups according to the risk of recurrence : very low risk, high risk or Intermediate risk. Little is known about this last group.

Anticoagulation is efficient to prevent recurrence but is currently not recommended for patient with an intermediate risk of recurrence.

Identifying risk factors of recurrent PE remains a major issue to identify sub-groups of patients who would require lifelong anticoagulation.

In 30-40% of cases, PE patients develop residual pulmonary vascular obstruction (RPVO), which has been found to be associated with an increased recurrence risk. This last observation was mostly reported in patients with unprovoked PE (patients with high risk of recurrence) and RPVO was measured using conventional planar lung scan.

In patients with an intermediate risk of recurrence, the impact of RPVO has been much less studied. In addition, the definition of RPVO was variable according to studies and correlation between RPVO burden and recurrence risk has not been clearly demonstrated. This might be explained by the inherent limitation of RPVO quantification using conventional planar imaging, which is only based on a visual estimation on 2-dimensional images.

Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT) is a new method of scintigraphic image acquisition that offers the advantage of 3-dimensional imaging, enabling more accurate and reproducible quantification of RPVO.

The main hypothesis of this study is that in patients with PE at intermediate risk of recurrence, RPVO computed with V/Q SPECT/CT imaging may be an important predictor of recurrence.

Study Overview

• Status: Recruiting
• Conditions: Venous Thromboembolism; Pulmonary Embolism
• Intervention / Treatment: Other: Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT)

• Study Type: Interventional
• Enrollment (Estimated): 665
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Pierre-Yves LE ROUX, Pr; Phone Number: +33298223327; Email: pierre-yves.leroux@chu-brest.fr

Study Locations

• France
  • Amiens, France, 80054
    • Active, not recruiting
    • CHU Amiens
  • Angers, France, 49933
    • Not yet recruiting
    • CHU Angers
    • Contact: Jeanne HERSANT, Pr; Phone Number: +33661392285; Email: Jeanne.hersant@chu-angers.fr
  • Brest, France, 29609
    • Recruiting
    • CHU Brest
    • Contact: Francis COUTURAUD, Pr
    • Contact: Pierre-Yves LE ROUX, Pr; Phone Number: +33298223327; Email: pierre-yves.leroux@chu-brest.fr
  • Colombes, France, 92700
    • Not yet recruiting
    • Hôpital Louis MourierAP-HP
    • Contact: Isabelle MAHE, Pr; Phone Number: +33147606490; Email: isabelle.mahe@lmr.aphp.fr
  • La Roche-sur-Yon, France, 85925
    • Recruiting
    • CHD VENDEE - La Roche sur Yon
    • Contact: Jean-Manuel KUBINA, Dr; Phone Number: +33251446301; Email: jean-manuel.kubina@ght85.fr
  • Le Kremlin-Bicêtre, France, 94270
    • Not yet recruiting
    • Kremlin-Bicêtre AP-HP
    • Contact: David MONTANI, Pr; Phone Number: +33145217976; Email: david.montani@aphp.fr
  • Les Sables-d'Olonne, France, 85340
    • Not yet recruiting
    • CH Les Sables d'Olonne
    • Contact: Nicolas BREBION; Phone Number: +33251218824; Email: nicolas.brebion@ght85.fr
  • Paris, France, 75015
    • Not yet recruiting
    • Hegp Ap-Hp
    • Contact: Olivier Sanchez, Pr; Phone Number: +33165093487; Email: olivier.sanchez@aphp.fr
  • Quimper, France, 29000
    • Recruiting
    • CH Quimper
    • Contact: Charles ORIONE, Dr; Phone Number: +33298526096; Email: charles.orione@ch-cornouaille.fr
  • Saint-Étienne, France, 42055
    • Not yet recruiting
    • CHU St-Etienne
    • Contact: Laurent BERTOLETTI, Pr; Phone Number: +33477127770; Email: laurent.bertoletti@chu-st-etienne.fr
  • Toulon, France, 83056
    • Not yet recruiting
    • CHIC Toulon
    • Contact: Jean-Noël POGGI, Dr; Phone Number: +33494145787; Email: jean-noel.poggi@ch-toulon.fr
  • Toulon, France, 83800
    • Not yet recruiting
    • HIA Toulon
    • Contact: Antoine-Raphaël BRONSTEIN, Dr; Phone Number: +33483162553; Email: antoine-raphael.bronstein@intradef.gouv.fr
  • Toulouse, France, 31059
    • Not yet recruiting
    • CHU Toulouse
    • Contact: Alessandra BURA-RIVIERE, Pr; Phone Number: +33561322438; Email: bura-riviere.a@chu-toulouse.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients ≥ 18 years,
• who experienced an objectively proven PE,
• who have been treated initially with anticoagulant therapy for 3 to 6 uninterrupted months (180 - 210 days) and for whom anticoagulation will not be prolonged.

Exclusion Criteria:

• Unwilling or unable to give written informed consent (protected adults, under tutorship or curatorship)
• Patients deprived of their liberty by a judicial or administrative decision, patients undergoing psychiatric care by virtue of Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8 and patients admitted to a health or social establishment for purposes other than research
• No Social security affiliation
• Isolated DVT
• Pregnant women,parturients women
• Other indication for anticoagulant therapy (e.g. atrial fibrillation, mechanic valve)
• Life expectancy < 6 months
• Any patients for whom there is a strong indication to treat longer than 6 months: PE provoked by a major persistent factor (e.g. cancer) or Recurrent unprovoked PE
• PE provoked by a major transient risk factor

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Patients with PE who have been treated with anticoagulant therapy for 3 to 6 uninterrupted months; Patients who experienced an objectively proven PE who have been treated initially with anticoagulant therapy for 3 to 6 uninterrupted months (180 - 210 days) and for whom anticoagulation will not be prolonged.	Other: Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT); All patients will undergo a V/Q SPECT/CT scan at inclusion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Symptomatic recurrent venous thromboembolism (VTE), including objectively confirmed nonfatal symptomatic PE or proximal deep vein thrombosis or fatal PE during a 24-month follow-up after inclusion in the study	In case of a suspected VTE or death during follow-up, the study personnel will collect related clinical data on the electronic case report form, and prepare an adjudication file, including symptoms, clinical notes, hospital discharge summary, and results of all diagnostic tests. All suspicion of VTE recurrence will be adjudicated blindly by an independent central Clinical Events Committee. To assess the primary objective, RPVO will be defined by a perfusion mismatched defect of at least 5% of the whole lung, corresponding to a segmental defect. SPECT imaging should not be used at inclusion and should not result in proposing prolonged anticoagulation. SPECT images will be numerically stored and interpretation will be later performed independently by two nuclear medicine physicians who will be blinded to clinical history and the patient's outcome. Any difference in interpretation will be resolved by consensus.	From baseline to Month 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adjudicated symptomatic objectively confirmed recurrent VTE during the follow-up period.		From baseline to Month 24
Percentage of patients with RPVO (as defined by a perfusion defect > 5%) on V/Q SPECT/CT imaging at inclusion in the study.		Inclusion
Different cut-offs of pulmonary vascular obstruction index will be evaluated to predict the risk of VTE recurrence at 2 years, by generating ROC curves		Inclusion
Other predictors of adjudicated symptomatic objectively confirmed recurrent VTE at 2 years including: age		Inclusion
The following score will be computed : HERDOO2 (Hyperpigmentation, Edema, Redness, D-Dimer, Obesity, Old)	Prediction score of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism recurrence in patients with unprovoked PE, (test in patients at intermediate risk of recurrence in this trial). Patient with score of 0 to 1 have a low risk of recurrent VTE, whereas patient with a score of at least 2, have a high risk of recurrence	Inclusion
Potential predictors of RPVO including : demographics		Inclusion
Symptomatic recurrent VTE during a 3 Months follow-up period in patients with suspicion of PE recurrence who has been left untreated based on a negative V/Q SPECT/CT scan	Symptomatic recurrent VTE including objectively confirmed nonfatal symptomatic PE or proximal DVT or fatal VTE	3 Months follow-up period after the suspicion of PE recurrence
Dyspnea index will be assessed using mMRC scale (Modified Medical Research Council)	The mMRC scale is a self-assessment tool used to measure the level of impairment caused by breathlessness during daily activities, rated on a scale from 0 to 4.[2] 0, no breathlessness except on strenuous exercise and 4, too breathless to leave the house, or breathless when dressing or undressing.	Inclusion and Month 6
Quality of life (QoL) will be assessed using PEmb-Qol (Pulmonary Embolism Quality of Life)	The PEmb-QoL is a validated 40-item questionnaire to quantify health-related quality of life in patients having experienced pulmonary embolism (PE). It covers six health dimensions: frequency of complaints, activities of daily living limitations, work-related problems, social limitations, intensity of complaints, and emotional complaints.The PEmb-QoL dimension scores are calculated by taking the mean of the constituting items. Dimension scores are then transformed to a scale from 0-100 to make them comparable across dimensions, with higher scores indicating worse outcome.	Inclusion and Month 6
Number of Participants with chronic thromboembolic pulmonary hypertension (CTEPH).	CTEPH will be defined by a mean pulmonary artery pressure >20 mmHg.	From baseline to Month 24
Mortality of all causes.		From baseline to Month 24
Percentage of patients with RPVO (> 5%) on V/Q SPECT/CT imaging using Technegas and Krypton.		Inclusion
The following score will be computed : PADIS-PE score.	PADIS-PE (score derived from the PADIS study : Prolonged Anticoagulation During eighteen months versus placebo after Initial Six-month treatment for a first episode of idiopathic Pulmonary Embolism randomized trial). A higher score indicates a higher risk of recidive.	Inclusion
Other predictors of adjudicated symptomatic objectively confirmed recurrent VTE at 2 years including: gender		Inclusion
Other predictors of adjudicated symptomatic objectively confirmed recurrent VTE at 2 years including: obesity	Body Mass Index > 30 kg/m2	Inclusion
Other predictors of adjudicated symptomatic objectively confirmed recurrent VTE at 2 years including: D-Dimer	Measurement of the concentration of plasma D-dimer	Inclusion
Other predictors of adjudicated symptomatic objectively confirmed recurrent VTE at 2 years including: inherited or acquired thrombophilia	Number of Participants with inherited or acquired thrombophilia	Inclusion
Other predictors of adjudicated symptomatic objectively confirmed recurrent VTE at 2 years including: residual vein thrombosis	Number of Participants with residual vein thrombosis	Inclusion

Collaborators and Investigators

• Sponsor: University Hospital, Brest

Study record dates

Study Major Dates

• Study Start (Actual): June 11, 2024
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): March 1, 2029

Study Registration Dates

• First Submitted: March 11, 2024
• First Submitted That Met QC Criteria: April 15, 2024
• First Posted (Actual): April 18, 2024

Study Record Updates

• Last Update Posted (Estimated): November 1, 2024
• Last Update Submitted That Met QC Criteria: October 30, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Keywords: venous thromboembolism recurrence
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Disease Attributes; Respiratory Tract Diseases; Lung Diseases; Embolism and Thrombosis; Recurrence; Pulmonary Embolism; Embolism; Thromboembolism; Venous Thromboembolism
• Other Study ID Numbers: 29BRC23.0161; 2023-A01566-39 (Other Identifier: IDRCB)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All collected data that underlie results in a publication
• IPD Sharing Time Frame: Data will be available beginning five years and ending fifteen years following the final study report completion.
• IPD Sharing Access Criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No